Spots Global Cancer Trial Database for Nivolumab in AML in Remission at High Risk for Relapse

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Nivolumab in AML in Remission at High Risk for Relapse

Official Title: PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for Relapse

Study ID: NCT02532231

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Adult Acute Myeloid Leukemia in Remission

Blasts Under 10 Percent of Bone Marrow Nucleated Cells

Therapy-Related Myeloid Neoplasm

Interventions

Laboratory Biomarker Analysis

Nivolumab

Study Description

Brief Summary: This phase II trial studies how well nivolumab works in treating patients with acute myeloid leukemia that has decreased or disappeared but may still be in the body (remission), and is at high risk for returning (relapse). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Detailed Description: PRIMARY OBJECTIVES: I. To evaluate the anti-leukemic effects of nivolumab in patients with acute myeloid leukemia (AML) who have achieved a 1st complete remission (CR) after induction chemotherapy and consolidation chemotherapy and have high risk for relapse, or have achieved a 2nd CR. SECONDARY OBJECTIVES: I. To evaluate the immunologic responses to nivolumab among patients with AML in CR status post standard chemotherapy. II. To determine whether response to nivolumab correlates with immunologic responses. III. To evaluate assessment of minimal residual disease (MRD) by flow cytometry as a predictor of response to immune therapy in treatment of AML and changes during the course of therapy with nivolumab. IV. To evaluate time to relapse and overall survival. V. To evaluate the toxicity profile of nivolumab among patients with AML in CR. OUTLINE: Patients receive nivolumab intravenously (IV) over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After cycle 6, patients may receive nivolumab on day 1 only. After cycle 12, patients may receive nivolumab on day 1 of every 3 cycles. Patients experiencing disease progression may go back to receiving treatment on days 1 and 15 of each cycle. After completion of study treatment, patients are followed up for 30 days.